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Introduction: The functional relevance of synovial ectopic lymphoid neogenesis (ELN) in rheumatoid arthritis (RA)
remains unknown. As ELN correlates with the degree of tissue inflammation, we investigated whether ELN was
associated with specific cytokine profiles.
Methods: Synovial ELN was determined by immunohistology and long CD21 isoform (CD21L) expression. Cytokine
expression was determined by multiplex enzyme-linked immunosorbent assay (ELISA) and quantitative polymerase
chain reaction (PCR) as well as immunohistology in synovial fluid (SF) (n = 44) and tissue (ST) (n = 108), respectively.
Production of ELN-associated chemokines by fibroblast-like synoviocytes (FLS) was studied in vitro.
Results: Screening analysis of SF by multiplex ELISA showed higher protein levels of interleukin (IL)-23 (p = 0.018)
and IL-17F (p = 0.028) in ELN+ versus ELN- samples. Other cytokines, including IL-17A, IL-6, and tumor necrosis factor
(TNF)-α, were not different. The association between IL-23 and ELN was not biased by disease activity or other
clinical features and was confirmed by higher IL-23 mRNA expression in ELN+ versus ELN- ST samples (p = 0.030), a
correlation between IL-23 and CD21L expression in the same samples (r = 0.70 p < 0.0001), and a similar correlation
in two independent ST sample sets (r = 0.778 p < 0.0001 and r = 0.817 p = 0.011). IL-23 p19 staining was neither
restricted nor enhanced in close proximity of ectopic lymphoid follicles, and neither IL-23 nor IL-17A stimulation
induced expression of the ELN-associated CC chemokine ligand, CCL21 and CXC chemokine ligand CXCL13, by FLS.
Downstream of IL-23, CD21L expression was significantly associated with IL-17F, IL-21, and IL-22, but not IL-17A in
two independent ST sample sets.
Conclusions: Synovial ELN in RA is strongly associated with activation of the IL-23 pathway but not with IL-17A.Introduction
Ectopic lymphoid neogenesis (ELN) is a histological
feature describing the organized aggregation in nonlym-
phoid tissues of T and B lymphocytes and, in a propor-
tion of cases, follicular dendritic cells (FDC) around
newly developed vessels called high endothelial venules
(HEV), which are similar to those found in lymphoid or-
gans [1, 2]. ELN has been described in multiple different* Correspondence: jcanete@clinic.ub.es; d.l.baeten@amc.uva.nl
1Arthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona and
IDIBAPS, c/ Villarroel, 170, 08036 Barcelona, Spain
2Amsterdam Rheumatology and Immunology Center/Department of Clinical
Immunology and Rheumatology, Academic Medical Center/University of
Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Full list of author information is available at the end of the article
© 2015 Cañete et al. This is an Open Access a
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/organs and tissues during inflammation, including syn-
ovial tissue (ST) in rheumatoid arthritis (RA) as well as
other forms of inflammatory arthritis [3–5]. ELN is asso-
ciated to in situ expression of cytokines and chemokines
such as lymphotoxin (LT)β, CXC chemokine ligand
(CXCL)13 and CC chemokine ligand (CCL)21 [6, 7] and
the expression of these factors is sufficient to induce
ELN in transgenic models [8–10]. The specific micro-
architecture and cellular composition of ELN suggests a
role in immune responses and potentially autoimmunity
[5, 11]. Although experimental evidence indicates that
ELN+ ST can produce autoantibodies [12], a series of
large translational studies failed to demonstrate a link
between synovial ELN and systemic or local RA-specific
antibodies [5, 13, 14]. Moreover, the presence of synovialrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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logical RA phenotype as associations with disease activ-
ity, disease severity and response to anti-tumor necrosis
factor (TNF)-α treatment were weak and inconsistent [5,
13, 14]. Accordingly, the pathogenic and clinical signifi-
cance of synovial ELN still remains unclear.
As we previously observed a clear association between
ELN and the histological degree of inflammatory infiltra-
tion in ST [5, 13], we postulated that there might be an
autoantibody-independent link between ELN and synovial
inflammation. In line with emerging evidence that B cells
are potent cytokine producers and antigen-presenting cells
[15, 16], it was reported that T cell activation in rheuma-
toid synovitis is B cell-dependent [17]. We therefore hy-
pothesized that the specific T/B cell organization observed
in synovial ELN may be associated with a specific T cell
cytokine profile. To test this hypothesis we investigated
the local expression of T helper (Th)1, Th2, Th17, and
proinflammatory cytokines in RA patients with and with-
out synovial ELN.
Methods
Patients and synovial tissues
Synovial biopsy specimens were obtained by needle arth-
roscopy in 108 patients fulfilling the American College
of Rheumatology (ACR) criteria for RA [18] who had
clinically active arthritis of at least one knee joint. None
of the patients had been treated with biological therapy
at time of inclusion. Arthroscopy was performed under
diagnostic and/or therapeutic (lavage) indication with a
2.7 mm arthroscope (Storz, Tullingen, Germany). Eight
samples were obtained from the suprapatellar pouch andTable 1 Demographic and clinical data of RA patients from cohort
neogenesis (ELN)
Total (n = 63)
Female, n (%) 41 (65)
Age (years) 59 (49; 69)
Disease duration (years) 12.0 (4.8; 17.8)
Tender joint count 3 (1; 10)
Swollen joint count 5 (2; 9)
C-reactive protein (mg/dL) 2.4 (1.1; 4.2)
ESR (mm/h) 33 (19; 67)
DAS28 4.4 (3.3; 5.5)
RF (IU) 128 (24; 257)
ACPA (IU) 254 (0; 782)
Number of DMARDs taken before biopsy 2 (1; 3)
Number (%) of patients taking oral steroidsa 46 (73)
Data are expressed as median (IQR), or frequency (%)
NS nonsignificant, ESR erythrocyte sedimentation rate, DAS28 28-item disease activi
peptide/protein antibodies, DMARDs, disease-modifying antirheumatic drugs
aAll of them ≤ 5 mg prednisonethe medial and lateral gutter in each patient [14]. Four
samples were fixed in 4 % formaldehyde and embedded in
paraffin wax for immunohistochemistry and the remaining
four collected on RLT lysis buffer (Qiagen, Crawley, UK)
for RNA extraction.
A first cohort, used for exploratory analysis of correla-
tions between ELN and cytokine expression, consisted of
63 RA patients. Demographics and clinical data are sum-
marized in Table 1. In a subgroup of these patients (n =
44), synovial fluid (SF) collected at the time of the arthros-
copy was centrifuged and frozen at −80 °C. Additional
synovial biopsies were obtained from an independent
confirmation cohort of 36 RA patients fulfilling the ACR
criteria (72 % female, mean age 65 years) with a mean 28-
joint disease activity score (DAS28) of 5.6 and a mean
C-reactive protein (CRP) of 1.53 mg/dL. Finally, synovial
biopsies for analysis of T cell transcription factors were
obtained from a third independent cohort consisting of
nine RA patients fulfilling the ACR criteria (89 % female,
mean age 57 years) with a mean DAS28 of 7.3 and a mean
CRP of 6.69 mg/dL). All patients gave written informed
consent. The present study was approved by the institu-
tional ethics committee of both participating centers
(Clinical Research Ethics Committee of the Hospital Clinic
of Barcelona, Barcelona, Spain, and Medical Ethics
Committee of the Academic Medical Center/University
of Amsterdam, Amsterdam, the Netherlands).
Immunohistochemistry
Sequential sections of RA ST were analyzed for the pres-
ence of lymphoid aggregates and the expression of the
following markers by peroxidase immunohistochemical1 stratified by presence or absence of ectopic lymphoid
ELN+ ELN– p value
n = 30 (47.6 %) n = 33 (52.4 %)
21 (70) 20 (61) NS
56 (50; 64) 62 (49; 70) NS
9.1 (3.9; 17.8) 13.1 (10.5; 17.8) NS
4 (2; 10) 2 (1; 10) NS
6 (2; 10) 3 (1; 8) NS
2.7 (1.4; 5.1) 2.1 (0.7; 3.8) NS
35 (19; 67) 31 (18; 53) NS
5.1 (3.9; 5.7) 4.0 (3.0; 4.9) 0.039
138 (61; 256) 74 (17; 325) NS
257 (0; 701) 251 (0; 822) NS
2 (1; 3) 2 (1; 4) NS
23 (76) 23 (70) NS
ty score, RF rheumatoid factor, IU international units, ACPA anti-citrullinated
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polyclonal antibody (A0452, Dako, Cambridge, UK), B
cells with mouse anti-human CD20 antibody (clone L26,
Dako), HEV with rat anti-human peripheral lymph node
addressin (PNAd) antibody (clone MECA-79, PharMin-
gen, Oxford, UK) and macrophages with MoA anti-CD68
(clone KP-1, Dako). Antigen retrieval, which was required
for most antibodies, was performed by microwave heating
in 1 mM ethylenediaminetetraacetic acid (EDTA) for
15 min. Primary antibodies were detected with appro-
priate secondary biotinylated antibodies using a biotin
peroxidase-based method (ABC, Vector Laboratories,
Burlingame, CA, USA) and diaminobenzidine as the
chromogen. Parallel sections were incubated with irrele-
vant isotype- and concentration-matched monoclonal
antibodies as negative control. Sections were finally
counterstained in Gill’s hematoxylin.
Analysis of lymphoid aggregates
The highest grade of lymphoid aggregation within each
sample was determined according to a previously de-
scribed scoring method [6] based on the number of
radial cell counts: grade 1 = 2–5 radial cell counts, grade
2 = 6–10 radial cell counts, and grade 3= > 10 radial cell
counts. T/B cell segregation and PNAd-positive HEV
within lymphoid aggregates was analyzed. ELN was
histologically defined as the presence of follicular aggre-
gates grade ≥ 2 with T/B cell segregation and HEV. To
define ELN at the molecular level, we performed quanti-
tative real-time polymerase chain reaction (qRT-PCR)
for CD21 long isoform (CD21L). This isoform of CD21
confers unique functions of FDCs in germinal center de-
velopment [19] and is selectively expressed in germinal
center-containing synovial tissues [1].
Quantification of cytokines in synovial fluid
SF cytokines were analyzed using Quantibody® Human
TH17 Array 1 (granulocyte macrophage colony-stimulating
factor (GM-CSF), interleukin (IL)1-β, IL-2, IL-4, IL-5, IL-6,
IL-10, IL-12p70, IL-13, IL-17A, IL-17F, IL-21, IL-22, IL-23,
interferon gamma (IFNγ), CCL20, transforming growth
factor beta 1 (TGF-β1), TNF-α and TNF-β) (RayBiotech,
Norcross, GA, USA) according to the manufacturer’s speci-
fications. Each sample was prepared in quadruplicate. An
Axon scanner 4000B with GenePix software (Molecular
Devices, Sunnyvale, CA, USA) was used to collect fluores-
cence intensities. Detection limits for cytokines are dis-
played on the manufacturer’s website [20].
Real-time quantitative PCR
Total RNA was extracted from ST samples according to
the recommendations of the RNeasy FFPE Kit (Qiagen,
Crawley, UK). The quality of the RNA was assessed by
nanodrop (NanoVue Plus, General Electric, Frieburg,Germany) and 1–2 micrograms of RNA was transcribed
into complementary deoxyribonucleic acid (cDNA) using a
high-capacity cDNA Archive Kit (Applied Biosystems,
Warrington, UK). TaqMan gene expression assays for hu-
man glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(4310884E), CD21L (Hs00153398), TNF-α (Hs001741
28_m1); IL-1β (Hs01555410_m1), IFN-γ (Hs009892
91_m1), IL-2 (Hs00174114_m1), IL-6 (Hs00174131_m1),
IL-17A (Hs00936345_m1), IL-17F (Hs00369400_m1),
IL-21 (Hs00222327_m1), IL-22 (Hs01574154_m1), IL-23
(Hs00372324_m1), RAR-related orphan receptor C (RorC)
(Hs01076122_m1), T-box 21 (TBX21) (Hs00203436_m1),
GATA binding protein 3 (Gata3) (Hs00231122_m1), aryl
hydrocarbon receptor (Ahr) (Hs00169233_m1), forkhead
box P3 (FoxP3) (Hs01085834_m1) and B-cell CLL/lymph-
oma 6 (Bcl6) (Hs00153368_m1) were purchased from
Applied Biosystems, and gene expression was measured in
duplex reactions. The relative expression (represented in
arbitrary units, a. u.) was calculated with the “2^(−ddCt)
method”, where dCt = Ctgene-Cthousekeeping gene, ddCt =
dCtsample-dCtcalibrator. In our analysis, we used GAPDH as
a housekeeping gene and one of the samples as an internal
calibrator [21]. The results were calculated using the Ste-
pOne Software v 2.1 (Applied Biosystems).
Immunofluorescence
Frozen synovial biopsy tissue sections were used for
double staining of IL-23-positive cells. The staining was
performed with monoclonal mouse anti-human IL-23
p19 (clone eBio473P19, eBioscience, San Diego, CA,
USA) in combination with biotinylated monoclonal anti-
bodies against macrophages (CD68, clone Y1/82A, Biole-
gend, San Diego, CA, USA) and stromal cells (vimentin,
(D21H3) XP™ rabbit monoclonal antibody, Cell Signaling
Technology, Danvers, MA, USA). Incubation with the pri-
mary antibodies was carried out overnight at 4 °C,
followed by incubation with a secondary Alexa Fluor 488-
conjugated goat anti-mouse antibody and streptavidin-
Alexa Fluor 594 (in case of staining with CD68) and
secondary Alexa Fluor 594-conjugated goat anti-rabbit
antibody (in case of staining with vimentin) was used.
Slides were mounted with Vectashield containing 4′,6-dia-
midino-2-phenylindole (DAPI) (Vector Laboratories) and
analyzed on a fluorescent imaging microscope (Leica
DMRA, Wetzlar, Germany) coupled to a CCD camera
and Image-Pro Plus software (Media Cybernetics, Dutch
Vision Components, Breda, the Netherlands).
Fibroblast-like synoviocytes cultures
Fibroblast-like-synoviocytes (FLS) cells were grown in
Dulbecco’s modified Eagle’s medium (Lonza, Basel,
Switzerland) containing 4.5 g/l glucose and supple-
mented with 10 % fetal bovine serum (FBS), 2 mM
glutamine, penicillin (100 u/ml) and streptomycin
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atmosphere containing 5 % CO2 at 37 °C.
Triplicate cultures from three different FLS lines from
RA patients (1.2 × 104 cells/cm2) were seeded in 6-well
culture dishes at passage 5–6 and allowed to adhere
overnight. Thereafter, the cells were cultured in the ab-
sence or presence of recombinant human IL-17A (R&D
Systems, Minneapolis, MN, USA) or IL-23 (Miltenyi
Biotech, Bergisch Gladbach, Germany) (10 ng/ml) for
24 hours in FLS culture medium. Nonstimulated cells
served as control.
Relative expression levels of CXCL13 and CCL21 mes-
senger ribonucleic acid (mRNA) were determined by qRT-
PCR. Induction of RANKL or MMP-1 mRNA was used as
positive control for the response to IL-23 and IL-17, re-
spectively [22, 23]. Total RNA from FLS was isolated using
TRIReagent (Sigma-Aldrich, St Louis, MO, USA) according
to the manufacturer’s instructions. The RNA concentration
and quality were determined with a Nanodrop ND-1000
spectrophotometer (Thermo Fisher Scientific, Waltham,
MA, USA). Subsequently, 1 μg RNA was reverse tran-
scribed using High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems). qRT-PCR were performed by
Applied Biosystems 7500 Fast Real-Time PCR System using
Power Syber Green PCR Master Mix. Relative gene expres-
sion was determined as described previously [24].
Statistical analysis
Numerical variables were described as median and inter-
quartile range (IQR) and categorical variables as fre-
quencies and percentages. The Wilcoxon rank-sum test
or Mann–Whitney test were used to compare the distri-
bution of numerical variables between groups. Fisher’s
exact test was used to compare categorical variables.
Correlation between numerical variables was expressed
using Spearman’s correlation coefficient. Correlation
between two categorical variables or between one nu-
merical and one categorical variable was assessed using
Fisher’s exact test and the Wilcoxon rank-sum test. As
single cytokines were correlated with ELN but not with
each other, Bonferroni correction for multiple dependent
correlations was not applied; confirmation of the find-
ings in an independent sample set was used to exclude
false-positive findings. All analyses were performed using
the SPSS v14 (SPSS Inc., Chicago, IL, USA) and STATA
v10 (StataCorp, College Station, TX, USA) programs, ex-
cept for SF cytokines. Cytokine data analysis was per-
formed using SPSS 18.0 (IBM Corp, Armonk, NY, USA).
Results
Histological and molecular characterization of synovial
ectopic lymphoid neogenesis
Thirty out of sixty-three patients (48 %) of the explora-
tory cohort (Table 1) had synovial ELN defined as thepresence of follicular aggregates grade ≥ 2 with T/B cell
segregation and HEV. There were no demographic or
clinical differences between ELN+ and ELN- patients
with exception of a higher DAS28 score in ELN+ pa-
tients (median 5.1; range 3.9–5.7) versus ELN- patients
(4.0; 3.0–4.9) (p = 0.039) (Table 1). However, other mea-
sures of disease activity such as C-reactive protein (CRP),
erytrocyte sedimentation rate (ESR), swollen joint count
(SJC) and tender joint counts (TJC) were not different be-
tween both groups. In agreement with previous studies [5,
13, 14], there were also no differences in disease duration
and in presence and/or titers of rheumatoid factor (RF)
and anti-citrullinated peptide/protein antibody (ACPA)
(Table 1). Histological analysis showed a significantly in-
creased infiltration with CD3+ T lymphocytes (p < 0.001)
(Fig. 1a and b) and CD20+ B lymphocytes (p < 0.001)
(Fig. 1c and d) in ELN+ versus ELN- synovial tissue sam-
ples. Infiltration of the synovial lining layer and the syn-
ovial sublining with CD68+ macrophages was similar in
both groups (Fig. 1e and f). Analysis of CD21L mRNA as
molecular marker for ELN confirmed significantly in-
creased expression levels in ELN+ versus ELN- synovial
tissue samples (p = 0.014) (Fig. 1g).
Increased synovial fluid levels of IL-23 and IL-17F in the
presence of synovial ectopic lymphoid neogenesis
To assess whether synovial ELN is associated with a spe-
cific proinflammatory cytokine profile, we first assessed
SF levels of Th1, Th2, Th17 and proinflammatory cyto-
kines in 25 ELN+ versus 19 ELN- samples. The expres-
sion of many cytokines including the Th2 cytokines IL-4,
IL-5 and IL-13 were low to undetectable in SF independ-
ently of the presence of ELN (data not shown). Strik-
ingly, however, SF levels of IL-23 (p = 0.018) and IL-17F
(p = 0.028) were significantly increased in ELN+ versus
ELN- samples (Fig. 2a and b). There was also a numerical
but not statistically significant increase in IL-22 (p = 0.070),
TGF-β1 (p = 0.060), and IFN-γ (p = 0.052) (data not
shown). Other proinflammatory cytokines implicated in
RA inflammation such as IL-6 and TNF-α (Fig. 2c and d)
were not different between both groups, indicating that the
increase in IL-23 and IL-17F is not merely reflecting in-
creased local disease activity in ELN+ synovitis.
Confirmation of the association between IL-23 and
synovial ectopic lymphoid neogenesis
As the SF screening revealed elevated IL-23 levels in
ELN+ versus ELN- samples, we next performed a series
of experiments to confirm this association. First, quantita-
tive polymerase chain reaction (PCR) on synovial tissue
biopsies indicated increased mRNA expression of IL-23
(p = 0.030) in ELN+ (n = 30) versus ELN- (n = 33) samples
from cohort 1 (Fig. 3a). Again, this association was specific






















Fig. 1 Immunohistological analysis of the cellular infiltrate in synovial membrane of RA patients from cohort 1 stratified according to ectopic
lymphoid neogenesis (ELN). a and b CD3+ lymphocytes. c and d CD20+ B lymphocytes. e and f CD68+ macrophages. g Relative mRNA expression of
CD21L in histologically defined ELN (negative or positive). CD21L CD21 long isoform, mRNA messenger ribonucleic acid, RA rheumatoid arthritis
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both groups (Fig. 3b and c). Second, IL-23 mRNA expres-
sion was also significantly correlated with mRNA expres-
sion of CD21L as molecular marker of ELN (r = 0.70; p <
0.0001) (Fig. 3d), thereby excluding a potential bias by
histological misclassification of samples with regard to
ELN. Third, this association was not biased by disease ac-
tivity as there was no significant correlation between ST
expression of IL-23 and measures of disease activity such
as DAS28 and CRP (data not shown). Finally, we could
confirm the correlation between synovial CD21L mRNA
and IL-23 mRNA expression in two additional and inde-
pendent sample sets [r = 0.778, p < 0.0001 in the first con-
firmation cohort of 36 synovial tissue samples (cohort 2)
(Fig. 3e) and r = 0.817, p = 0.011 in the second confirm-
ation cohort of nine synovial tissue samples (cohort 3)
(Fig. 3f)]. Collectively, the different approaches and the
use of different independent cohorts confirmed a robust,
technically and biologically reproducible correlation be-
tween synovial IL-23 and ELN.
Exploration of the functional relationship between IL-23
and ectopic lymphoid neogenesis
In order to explore if synovial ELN might be IL-23-
dependent, we first immunostained IL-23 protein in syn-
ovial biopsy samples. As shown in Fig. 4, clear staining
for IL-23 was detected throughout the synovial biopsysections. The p19 staining was neither restricted nor en-
hanced in close proximity of ectopic lymphoid follicles,
indicating that ELN does not form a microarchitectural
niche for IL-23-producing cells (Fig. 4a and b). Interest-
ingly, double staining indicated that the IL-23-specific
p19 subunit was not only expressed by CD68+ macro-
phages but also by vimentin-positive stromal cells
(Fig. 4c). Control stainings with isotype control con-
firmed the specificity of the anti-p19 stainings (Figure S1
in Additional file 1) We next investigated if IL-23 or IL-
17A stimulation of FLS in vitro leads to increased pro-
duction of CCL21 and CXCL13, two pivotal chemokines
in ELN. CCL21 and CXCL13 mRNA expression was
clearly detected under basal conditions in cultured RA
FLS, albeit CXCL13 expression was highly variable among
different FLS lines. However, neither CCL21 nor CXCL13
mRNA expression were significantly induced by either
IL17A or IL23 stimulation (Fig. 5). Thus, these in vitro
experiments did not provide clear evidence that ELN is
IL-23 dependent, but more thorough in vivo analysis re-
mains warranted.
Expression of IL-23-dependent cytokines in the presence
of ectopic lymphoid neogenesis
We next investigated if the increased expression of
IL-23 in ELN+ synovial tissue was associated with a
skewing of T cell cytokines toward a Th17 profile. In
Fig. 2 Synovial fluid cytokine levels as determined in RA patients from cohort 1 stratified according to ectopic lymphoid neogenesis (ELN).
IL-23 (a), IL-17F (b), IL-6 (c) and TNFa (d). Median and interquartile ranges are represented. RA rheumatoid arthritis. TNF-a: Tumor necrosis factor alpha-
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samples, mRNA expression analysis of synovial tissue
confirmed that CD21L was significantly correlated with
IL-17F (r = 0.42; p = 0.002) but not IL-17A (Fig. 6a and
d). Moreover, there was a clear correlation with IL-21
(r = 0.3; p = 0.049), and IL-22 (r = 0.33; p = 0.016) expres-
sion (Fig. 6b and c). Investigating the discrepancy be-
tween IL-17A and other IL-23-dependent cytokines, we
first repeated the same analysis in our validation cohort
(cohort 2). Also in this independent sample set, CD21L
as molecular marker of ELN showed a significant correl-
ation with IL-17F (r = 0.51; p = 0.015), IL-21 (r = 0.68;
p < 0.0001), IL-22 (r = 0.58; p < 0.002), but not IL-17A
(Fig. 6e-h). Second, further analysis of the SF protein
data in cohort 1 showed that SF IL-23 levels did strongly
correlate with IL-17F (r = 0.643; p < 0.0001), IL-22 (r =
0.606; p < 0.0001), and IL-21 (r = 0.698; p < 0.0001) but not
with IL-17A (p = 0.58) (Fig. 7). Confirming the specificityof these findings, IL-23 SF levels were not correlated to
the Th1 cytokines IL-2 and IFNγ (data not shown).
In an attempt to explore this striking discrepancy be-
tween IL-17A and other Th17 cytokines, we determined
the expression of key T cell transcription factors by
qPCR in the third cohort of synovial tissue samples.
Despite the small number of samples in this analysis,
there was a clear correlation between CD21L expression
and expression of GATA3 (r = 0.80; p = 0.001), TBX21
(r = 0.62; p = 0.077), and FoxP3 (r = 0.75; p = 0.020),
probably reflecting the higher T cell infiltration in ELN+
samples. Strikingly, however, there was no correlation
between either CD21L expression or IL-23 expression
and RORC.
Discussion
Synovial ELN is a well-recognized microarchitectural
feature of rheumatoid synovitis which clinical and
Fig. 3 Analysis of synovial tissue mRNA expression of IL-23 (a), IL-6 (b) and TNF-α (c) by quantitative PCR in the cohort 1 of RA. Analysis with
ectopic lymphoid neogenesis (ELN) based on the histology. Correlation of mRNA expression of CD21L (molecular marker of ELN) with expression
of IL-23 in the three RA cohorts (d-f). CD21L CD21 long isoform, IL interleukin, mRNA messenger ribonucleic acid, PCR polymerase chain reaction,
RA rheumatoid arthritis, TNF-α tumor necrosis factor alpha
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on indirect evidence, it has originally been suggested
that ELN may play a role in the breach of peripheral tol-
erance and thereby may fast-track autoimmunity [25].
Subsequent studies in large cohorts, however, consist-
ently reported that the presence and/or levels of auto-
antibodies such as RF and ACPA were not related to the
synovial ELN [5, 13, 14]. Exploring other potential links
between ELN and synovial inflammation, an original re-
port indicated that the presence of lymphoid follicles
was associated with high expression of IFNγ and IL-10
and low expression of IL-4 [26]. Gene expression profil-
ing of synovial tissue with ELN could, however, not
reproduce these data and, in contrast, found an upregu-
lation of the IL-7 pathway, which was suggested to pro-
mote ELN [27]. The present study, which was designed
to assess systematically the association between synovial
ELN and cytokines potentially involved in the pathogen-
esis of RA, could not reproduce the association with IL-7
but identifies for the first time a robust association be-
tween synovial ELN and increased expression of IL-23 and
downstream cytokines such as IL-17F, IL-21 and IL-22.
The validity of the findings is supported by several ob-
servations. First, the frequency of ELN, the absence of re-
lationship with clinical features such as disease durationand serological features such as RF and ACPA, and the
association with higher levels of lymphocytic infiltration
found in this study are perfectly in line with previously
published data [5, 13, 14]. Second, the correlation between
synovial ELN and activation of the IL-23 axis was technic-
ally and biologically reproducible using protein and
mRNA approaches, using histological and molecular
characterization of ELN, and across independent sample
sets. The latter exclude false-positive results based on
multiple comparisons or single outliers in the first cohort.
Moreover, correlation analysis in the first cohort and con-
firmation in the second cohort (where DAS28 and CRP
were similar in ELN+ and ELN- patients) confirmed that
the association between synovial ELN and IL-23 was not
biased by disease activity. Third, the robust correlation
between ELN and IL-23 was recently also found by us in
psoriatic arthritis (PsA) [28]. Finally, this association was
specific as there was no significant correlation between
ELN and other proinflammatory cytokines involved in RA
synovial inflammation such as IL-6 and TNF.
The potential meaning and function of the described
association between synovial ELN and activation of the
IL-23 should be interpreted cautiously. Our immuno-
pathological approach of synovitis allows the detection












Fig. 4 Cellular distribution of IL-23 in synovial membrane of RA patients. Double immunofluorescence analysis in RA synovium was performed
using specific antibodies against IL-23p19 (green), CD68 or vimentin (red). DAPI- (blue) stained nuclei. p19 double staining with CD68+ macrophages
showing that ELN does not form a microarchitectural niche for IL-23-producing cells (a and b). IL-23 expression by vimentin-positive stromal cells
(c). Magnification × 25. DAPI 4′,6-diamidino-2-phenylindole, IL interleukin, RA rheumatoid arthritis. ELN: ectopic lymphoid neogenesis
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tional experiments in vitro and in animal models to in-
vestigate whether ELN promotes activation of the IL-23
axis or, alternatively, IL-23/IL-17 cytokines drive ELN
and germinal center reactions. Interestingly, a series of
elegant studies in experimental arthritis demonstrated
that IL-17-producing Th cells and IL-17 orchestrate auto-
reactive germinal center development in autoimmune
BXD2 mice [29, 30]. This was confirmed by studies in ex-
perimental autoimmune encephalomyelitis indicating thatFig. 5 Relative expression levels of CXCL13 and CCL21 were determined b
mRNA was used as positive control for the response to IL-23 or IL-17, respe
interleukin, mRNA messenger ribonucleic acidTh17 cells are effective B cell helpers and induce ELN in
the inflamed central nervous system [31, 32]. Additionally,
a recent report indicates that Th17 cells can acquire a fol-
licular helper T cell phenotype and induced immuno-
globulin A (IgA)-producing germinal center B cells in the
intestinal Peyer’s patches [33]. These experimental data
emphasize the functional role of the IL-23/IL-17 axis in
germinal center reactions in tertiary and ectopic lymphoid
structures. In the setting of ELN in human RA synovium,
however, we did not observe preferential IL-23 p19y quantitative real-time-PCR (qRT-PCR). Induction of RANKL or MMP-1
ctively. CCL CC chemokine ligand, CXCL CXC chemokine ligand, IL
Fig. 6 Correlation between mRNA expression of CD21L (molecular marker of ELN) and Th17-related cytokines in the synovial tissue of cohort 1
(a-d) and cohort 2 (e-h). CD21L CD21 long isoform, ELN ectopic lymphoid neogenesis, mRNA messenger ribonucleic acid, Th T helper
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demonstrate an induction of ELN-associated chemo-
kines such as CCL21 and CXCL13 by exposure of FLS
to IL-23 and IL-17A.
Although we could thus not provide clear evidence
that synovial ELN is driven by the IL-23 axis and the po-
tential causal relationship between the two features thus
remains unknown, our further analysis revealed two in-
teresting features. First, immunofluorescence confirmed
IL-23 p19 expression by synovial myeloid cells such as
macrophages but also indicated p19 staining of vimentin-
positive stromal cells. Previous studies reported that FLS
can express p19 mRNA but not mRNA for the other IL-
23 subunit, p40 [34, 35]. The significance of this findingFig. 7 Spearman’s correlation between synovial fluid cytokine levels of IL-2
scale representation. IL interleukin, RA rheumatoid arthritisremains to be further investigated, also in the context of
ELN. Second, analysis of downstream cytokines of the IL-
23 axis consistently indicated a correlation between ELN
and protein and mRNA expression of IL-17F, IL-21, and
IL-22 but, surprisingly, not IL-17A. It is increasingly
recognized that IL-17A-producing cells, including canon-
ical Th17 cells, are plastic and that the activation of the
pathogenic IL-17A production module is transient and
dependent on a variety of factors. One interpretation of
our findings could thus be that the IL-23 axis is indeed ac-
tivated in ELN+ synovitis but that this is not associated
with activation of the pathogenic IL-17A production mod-
ule in RA synovitis. The absence of correlation between
ELN and RORC expression would be consistent with this3 with IL-17F, IL-22 and IL-21 as determined in RA patients. Logarithmic
Cañete et al. Arthritis Research & Therapy  (2015) 17:173 Page 10 of 12interpretation. Alternatively, IL-23 could act on other cell
types than canonical Th17 cells in the synovial tissue. Sev-
eral immunopathological studies of human synovitis in-
deed reported a pronounced IL-17A staining of mast cells
and, to a lesser degree, neutrophils while IL-17A-positive
T cell were virtually undetectable [36–39]. There are no
reports on the cellular source of IL-17F or IL-22 in human
synovium and a systemic analysis of synovial IL-23R-
positive cells is still lacking due to the absence of reliable
monoclonal tools. In the present study, we did not pursue
further the identification of IL-17F-, IL-21- and IL-22-
producing synovial cells as data of such immunohisto-
chemical analyses remain difficult to interpret for several
reasons. First, this approach indicates the presence of the
protein but not its production as the cytokine may, for ex-
ample, be accumulated on the surface of target cells ex-
pressing its specific receptor. Second, this technique may
be inappropriate to detect cells that continuously produce
and secrete a cytokine of interest as the amount of protein
within these cells would fall below the detection limit. Fi-
nally, this approach may miss rare cell populations such as
innate lymphoid cells which, despite their paucity, may
have important pathophysiological effects. Taken together,
the mandatory identification of the cellular source and
potential co-expression of different cytokines such as IL-
17A, IL-17F, IL-21 and IL-22 by single cells requires dif-
ferent technical approaches such as ex vivo FACS sorting
of specific highly purified cell populations for mRNA and
protein analysis for these cytokines. These ongoing experi-
ments fall beyond the scope of the present study on ELN.
Although causal relationship between synovial ELN
and activation of the IL-23/IL-17 cytokine axis remains
to be demonstrated, our study reveals for the first time a
robust biological correlate to the heterogeneity of the
histological microarchitecture of synovitis. The potential
relevance of this finding is twofold. First, ELN has not
only been observed in inflamed synovium but in many
other chronically inflamed tissues affected by auto-
immune diseases as well as chronic infections. The fact
that we found the association with IL-23 in both RA and
PsA [28] raise the hypothesis that this may be a global
feature of ELN, which is not restricted to a particular
disease or tissue. Second, phase two trials with mono-
clonal antibodies targeting IL-17A showed only modest
signs of efficacy in RA [40–42]. Moreover, the response
was not universal but heterogeneous between patients.
Our observations raise the question whether the pres-
ence of synovial ELN, which is strongly associated with
cytokines of the IL-23/IL-17 axis, could reflect this
therapeutic heterogeneity and whether targeting other
cytokines of the IL-23 axis, including IL-17F and IL-22,
may provide additional clinical benefit. Prospective
studies with baseline histological evaluation of ELN
and comparing treatment with drugs targeting differentcytokines of the IL-23 axis are warranted to address
this hypothesis.Conclusions
The present study, aimed to assess the association be-
tween synovial ELN and cytokines potentially involved
in the pathogenesis of RA, identifies for the first time a
robust association between synovial ELN and increased
expression of IL-23 and downstream cytokines such as
IL-17F, IL-21 and IL-22. These findings could reflect the
heterogeneity observed in the response to monoclonal
antibodies targeting IL17A in phase II clinical trials in
RA, and raise the question whether targeting other cyto-
kines of the IL-23 axis, including IL-17F and IL-22, may
provide additional clinical benefit.Additional file
Additional file 1: Figure S1. Immunohistological staining of IL-23p19
(1 ug) and istoype control (IC) in synovial membrane of RA patients.
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